NCT05398263: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 3 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05398263 |
|---|---|
| Title | A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SUNRISE) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 9, 2022 |
| Completion date | March 24, 2025 |
| Required reporting date | March 24, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |